About us

I-Mab is an innovative biopharmaceutical company with an exclusive focus on biologics with first-in-class and best-in-class potential in the therapeutic areas of immuno-oncology and immuno-inflammation. Our mission is to develop transformational medicines to address unmet medical needs and improve the lives of patients. To realize this goal, we strive to become a leading innovative biopharmaceutical company in China with global reach to discover, develop and commercialize potential first-in-class and best-in-class medicines.

We have embarked on a rapid development journey since the company was founded in 2017 by the merger between Third Venture Biotech (founded by Dr. Jingwu Zang, Tigermed and Bioscikin) and Tasgen (founded by I-Bridge Capital, Tasly Shanghai and Genexine Inc.). Headquartered in Shanghai with operational sites in Beijing and the United States, I-Mab is led by a management team that has a wealth of global industry leadership and R&D experience and is well represented by China’s top talent.

Our differentiated pipeline strategy is to build a risk-controlled clinical stage pipeline with an exclusive focus on potentially first-in-class and best-in-class biologics. To achieve a delicate balance between exclusive positioning of first-in-class and best-in-class therapeutics and the related development risk, we have built a globally competitive biologics pipeline comprised of a risk-controlled and “fast-to-market” China Portfolio and a transformational Global Portfolio.

Relying on our internal discovery capability and integrated R&D platforms, we developed a portfolio of globally competitive drug candidates that possess first-in-class or best-in-class potential. We own the intellectual property and full global rights of all assets in our Global Portfolio. These major pipeline assets take three different molecular formats: (1) monoclonal antibody, (2) antibody-cytokine fusion molecule (immuno-cytokine), and (3) bi-specific antibody. They work through novel or differentiated mechanisms to potentially translate into innovative medicines for cancer treatment. These molecules are expected to reach clinical development in the United States by 2019.

The China Portfolio consists of products that are positioned for serial BLAs expected in 2021 and onwards in China. All products under development are ready for Phase 2 or Phase 3 clinical trials and have first-in-class and best-in-class potential. These products have excellent development characteristics. For example, they are at relatively late development stages and involve clinically validated drug targets. All products have successfully passed Phase 1 or Phase 2 clinical trials with excellent safety and preliminary efficacy data (Phase 2 assets) in Europe or elsewhere. Therefore, these products have been significantly de-risked on their path towards BLA.

Currently, we are rapidly advancing our China Portfolio of late stage clinical assets towards market launch in China and pushing our Global Portfolio of innovative assets towards new clinical milestones in the United States. To achieve these goals, we intend to build our own manufacturing and commercialization capabilities to become an end-to-end fully-integrated biopharmaceutical company by 2021. Meanwhile, we continue to enrich and enhance our pipeline through selective in-licensing of highly competitive, innovative, and clinically advanced assets for the China Portfolio and through a new wave of novel drug candidates from our own discovery engine.

Our Vision

We are passionate about creating transformational therapies through innovation to address unmet medical needs for patients in China and around the world. China has the world’s fastest-moving environment and is ripe with tremendous opportunities.
We are keen to capitalize on a growing talent pool of professionals with both global and local R&D and business expertise, a critical mass of CRO services with global standard, a rapidly improving regulatory and drug innovation environment and large capital resources. These unique advantages in China, coupled with the huge market potential of China’s vast patient population and growing global reach, allow us to generate remarkable power and speed to develop innovative medicines. As an R&D company, we are uniquely positioned with a competitive pipeline and dynamic business strategy that capitalizes on these key advantages in this unique environment.

Driven by a compelling pipeline strategy, we have established a “Global Portfolio” and a “China Portfolio” of potentially first-in-class and best-in-class clinical and preclinical assets in the most exciting therapeutic areas of immuno-oncology and immuno-inflammation.

China Portfolio

  • Potential First-in-Class or Best-in Class
  • Clinically advanced assets entering Phase 2/3
  • Addressing highly unmet medical needs
  • Controlled development risk
  • Aiming for product launches from 2021 and onwards

Global Portfolio

  • Potential First-in-Class or Best-in Class
  • Assets discovered and developed internally
  • Possessing full global commercial rights
  • Aiming to conduct Ph1/2 clinical trials in US
  • Multiple assets to enter clinical development in 2019
We envision becoming a fully integrated biopharmaceutical company with manufacturing as well as commercialization capabilities, and launching serial products from 2021 and onwards.


Scroll to Learn More

Organization & Management Team

Our management team has both global and China pharma R&D expertise, ranging from discovery to CMC, regulatory, and clinical development. The senior management leaders have on average more than 15 years of pharma R&D experience. Our senior and mid-level management team is among China’s top talent in their respective fields of expertise, bringing together a core strength for the company.

Chairman and CEO Jingwu Zang, MD, PhD
I-Mab has built a globally competitive pipeline and a highly experienced team. We are passionate to develop transformational medicines to improve patients’ lives.

Dr. Zang obtained a medical degree from Shanghai JiaoTong University School of Medicine and a doctoral degree in immunology from the University of Brussels. He was a postdoctoral fellow at Harvard Medical School and obtained his U.S. medical license from the Texas Medical Board through a clinical residency at Baylor College of Medicine in Houston. 

Dr. Zang’s academic career started in Dr. Willems Institute and University of Limburg in Belgium. He became a professor at Baylor College of Medicine in Houston, USA and later joined the Chinese Academy of Sciences as the founding director for the Institute of Health Sciences and co-director for Institute Pasteur Shanghai. Dr. Zang has published more than 160 scientific papers in international journals such as Science, The Lancet, Nature Medicine, and Nature Immunology. He has also contributed to several books and book chapters. Since 2007, Dr. Zang held leadership positions in pharma R&D at GlaxoSmithKline, Simcere Pharmaceuticals and BioScinKin. Dr. Zang’s career prior to I-Mab Biopharma is highlighted by his academic research achievements, clinical experience, organizational management and innovative drug development in both global and China pharma settings.

Research and Development

Joan Huaqiong Shen

MD, PhD.

President of R&D

R&D is led by Joan Huaqiong Shen, MD, PhD, President of R&D. Dr. Shen is a US board-certified physician and holds a PhD in life sciences from Indiana University School of Medicine, where she was appointed as an adjunct professor in the department of psychiatry. She also completed fellowships in endocrinology, psychopharmacology and clinical pharmacology. Her scientific contributions have led to multiple research grant awards and more than 30 publications.

Dr. Shen’s pharmaceutical career began at Eli Lilly & Company and extended to various executive positions at Wyeth, Pfizer, Jiangsu Hengrui Medicine and Johnson & Johnson. She was the clinical head at Pfizer China and the chief medical officer at Jiangsu Hengrui Medicine, where she built the largest clinical team among Chinese domestic pharma companies and established successful clinical trials in China, US and Australia. At J&J, Dr. Shen served as China Development Head and oversaw all clinical development programs in China. Under her leadership, multiple innovative drugs were approved by China NMPA, including Sirturo, Olysio, Imbruvica, Simponi, and Stelara.

Dr. Shen was elected as the co-chair of the R&D-based Pharmaceutical Association in China’s (RDPAC) core R&D team She also sits in the China New Drug Research Evaluation Executive Committee and is currently the guest professor at the Beijing University Clinical Research Institute.

Under the leadership of Dr. Shen, the R&D organization is structured to include the following:Discovery led by Taylor Guo, PhD, Chief Scientific Officer; Pre-Clinical Development led by Bruce He, PhD; Regulatory Affairs led by Tiffany Liang, Head of the Beijing Site; Portfolio Management led by Chao Zhang, PhD; Medical Office (Pharmacovigilance and quality assurance) led by Yuan Meng, MD; Oncology Clinical Research led by Liping Wang, MD; Clinical Operations led by Michelle Yang, MS; and the US Site led by Claire Xu, MD, PhD; Our integrated R&D management team has extensive global pharma R&D expertise with many years of innovative drug development and managerial experience in their respective disciplines.

Chemistry, Manufacturing and Controls (CMC)

Zheru Zhang


President, Head of CMC & Manufacturing

The CMC group is headed by a global pharma CMC veteran Zheru Zhang, PhD., President, Head of CMC and Manufacturing. Dr. Zhang obtained his PhD in biochemistry from the University of Alberta, Canada. He has more than 20 years of experience in CMC development and quality management in the pharmaceutical industry in the US, Europe, Korea and China. He has extensive experience with various regulatory authorities, such as NMPA, FDA, EMA, MFDS, PMDA and TGA for biological products. Prior to joining I-Mab, Dr. Zhang held technical and management positions at Bristol-Myers Squibb and Johnson & Johnson. He also served as Vice President of Celltrion and President of Tasgen. During his pharma tenure, Dr. Zhang has led or participated in 20 biologics IND and six global BLA submissions, including the first biosimilar monoclonal antibody product approved in Europe, Japan and the United States.

Under the leadership of Dr. Zhang, the CMC organization is structured to include the following: process development function including the cell line development laboratory is led by Dr. Junhua Qiao; analytical and formulation development function including analytical development laboratory is led by Dr. Mountain Hsieh; project management team is led by Dr. Sheng Yin; quality assurance function is led by Mr. Jack Qin.


Jielun Zhu


Chief Financial Officer

As the Chief Financial Officer, Jielun Zhu, MBA, CFA, is in charge of the overall financial strategy and management, capital investment, corporate finance and investor relations. He is a veteran and expert in the finance industry, with over 11 years of experience in investment banking. From December 2015 to July 2018, prior to joining I-Mab, he served as a managing director and Asia Head of Healthcare Investment Banking and Capital Markets in Hong Kong for Jefferies Group LLC, a global full-service investment bank with a strong focus in healthcare.

At Jefferies, he advised many biotechnology and healthcare clients globally on IPOs and other financings, as well as mergers and acquisitions. From August 2008 to September 2015, he worked for the Deutsche Bank Group in its Hong Kong office. He occupied a succession of positions, with the last one being Director in the Corporate Finance Division, which entailed working with leading clients in the healthcare and other sectors in Greater China. From July 2007 to July 2008, he was an investment banker in Hong Kong with UBS AG. Before investment banking, Mr. Zhu was a strategy consultant in Boston focused on serving clients in the US pharmaceutical and biotechnology industry.

Mr. Zhu earned his M.B.A. from the Harvard Business School with distinction in June 2007 and his Bachelor of Arts degree with honors in mathematics-economics from Wesleyan University. He is also a CFA charter holder.

Global Business and Corporate Development

Weimin Tang


Executive Vice President of Global Business

The Global Business Development team and the Corporate Development team work closely to support I-Mab’s vision of becoming a fully integrated innovative biopharmaceutical company.

The Global Business Development team is led by Weimin Tang, PhD, who is responsible for the company’s overall business development strategy. Dr. Tang has a strong track record of successful global pharmaceutical business development. During his 15-year tenure in pharma BD, he worked at Pfizer, Bristol-Myers Squibb, Sanofi, and Johnson & Johnson. He also was Acting CEO of Hengrui Therapeutics, a US branch of Hengrui Pharmaceuticals. With broad experience in global and China marketplaces, the BD team works closely with other functions to identify external partnering opportunities and to help maintain a competitive pipeline. I-Mab remains actively engaged in in-licensing and out-licensing activities.

Raven Lin


Vice President of Corporate Development

Corporate Development is led by Raven Lin, PhD. His team provides long-term corporate development strategic direction, which covers global partnerships, alliance management, manufacturing capability and commercialization. The team is also focused on building an enterprise ecosystem that meets the company’s long-term business goals and financial strategies. Dr. Lin is an experienced BD executive with a strong track record in the pharmaceutical industry. He has a wealth of experience in licensing and M&A, project management, and marketing and sales from positions he held at Mycenax and SynCore Bio. He has successfully completed several BD and partnership deals at I-Mab.

Company Operations

Lili Qian


Vice President & Secretary of the Board of Directors

Company operations encompass HR, Administrative, Facilities, Legal, Procurement, Government Affairs, Public relations, and Auditing. The team is led by Vice President Dr. Lili Qian, PhD, who has extensive experience in R&D operations, including managing startup companies, budgeting, project management, fundraising, and government affairs. She previously worked at Simcere Pharmaceuticals and BioSciKin. Dr. Qian also serves as Secretary of the Board of Directors.


TigerMed and BioSciKin were early investors when Third Venture Biopharma was first founded in 2015. Series A financing of Third Venture was led by I-Bridge Capital in 2016. In 2017, Third Venture Biopharma merged with Tasgen to become I-Mab Biopharma and subsequently completed the Series B financing of $150 million. The Series B round was led by C-Bridge Capital, with Tasly and Genexine participating. The Series C round of USD$220 million was completed in June 2018 and was led by Hony Capital, along with Hillhouse Capital, HOPU Investments, CDH Investment, Ally Bridge Group, Singapore-based EDB, and existing investors C-Bridge Capital and Tasly Capital. The proceeds of the financing will be primarily used to advance the preclinical and clinical development of the company’s core products and major pipeline assets with best-in-class and first-in-class potential.

About Hangzhou Tigermed Consulting

Hangzhou Tigermed Consulting Co., Ltd (SHE:300347) is a leading Contract Research Organization (CRO) in China dedicated to provide professional full clinical trial services. Since inception in 2004, Tigermed has been committed to accelerating medical product development with costs efficiency and quality.
Headquartered in Hangzhou, Tigermed operates 33 subsidiaries, 63 offices across China and 12 overseas offices in Hong Kong China, Taiwan China, USA, Switzerland, Canada, Korea, Australia, Japan, Malaysia, Singapore, India and Romania with over 3600 full time staffs. Tigermed has serviced more than 600 local and global clients in the conduct of over 1060 clinical trials. Tigermed is recognized as “The Innovative Clinical CRO” in China, owning to our involvement of  over 150 innovative drugs.

More information

About Genexine

Genexine, Inc., listed on KOSDAQ (095700) since 2009, is a clinical stage biotherapeutics company focused on the development and commercialization of  immuno-oncology and orphan disease. Genexine has robust pipelines in clinical and pre-clinical stages based on long-acting Fc fusion technology and therapeutic DNA technology.
Founded in 1999, Genexine has over 140 employees, and half of them are scientists with MSc, or Ph.D. Genexine is located in Pangyo Techno Valley near Seoul, Korea with a branch office in New York.

More information

About Simcere Pharmaceutical Group

Simcere is a research and development-driven Chinese pharmaceutical company committed to bringing high quality and more effective therapies to patients by combining in house R&D with partnerships. Simcere focuses its efforts on therapeutic areas of oncology, neurology, inflammation/immunology, cardiovascular and infectious diseases.
Simcere is dedicated to research & development of innovative pharmaceuticals and branded generic drugs in China, with a State Key Lab of Translational Medicine and Innovative Drug Development. By leverage of its commercial capability, all top products of the company have leading market share in China.
By leveraging partnering experience with multinational pharmaceutical companies and innovative biotech companies, Simcere continues to advance international medical scientific achievements transformation and create value for partners in China.

More information

About China Renaissance Group

China Renaissance Group is a leading financial institution that combines advisory services for private placements, M&A, securities underwriting, research, sales and trading, investment management and other financial services. Providing one-stop financial services across mainland China, Hong Kong and the United States, CR Group operates a competitive and unique international network that connects China’s capital markets with the rest of the world, serving new entrepreneurs and investors globally.

More information

About EDB

A government agency under Singapore’s Ministry of Trade and Industry, the Economic Development Board (EDB) is responsible for strategies that enhance Singapore’s position as a global center for business, innovation, and talent.

More information

About Ally Bridge Group

Ally Bridge Group is a global healthcare-focused investment group founded by Frank Yu. Mr. Yu and his team began investing in healthcare in China in 2011, and have since evolved into successful, global healthcare investors. Today, ABG and its affiliates manage close to US$2 billion in assets and a portfolio of some of the world’s most novel life sciences companies and technologies in the United States, Europe and China.

More information

About C-Bridge Capital

C-Bridge Capital is a healthcare-dedicated private equity firm, focused on growth and late-stage investment opportunities. C-Bridge Capital's current portfolio includes China's leading players in pharmaceuticals, medical devices, diagnostics and healthcare services. C-Bridge Capital currently manages more than US$700 million in assets. With the power of capital markets, C-Bridge Capital is committed to supporting commercialization of cutting-edge technologies and companies that fulfil unmet medical needs to improve the standard and quality of patient care.

More information

About Tasly

With more than 20 years of history, Tasly Group is one of the biggest pharmaceutical companies in China. Its business focuses on R&D, manufacturing and sales of modern traditional Chinese medicines, biologics and small molecules covering all the major therapeutic areas. Tasly’s products are registered in over 34 countries across the globe, and it owns one of the largest marketing and sales teams in China.

More information

About Hony Capital

Founded in 2003 and sponsored by Legend Holdings, Hony Capital specializes in buyout investments. It currently has USD$10 billion under management and includes investors from China and the world’s leading investment institutions. Hony Capital is committed to financial innovation, helping Chinese enterprises go global and for foreign enterprises to enter China. Since 2014, Hony Capital has established Hospital Corporation of China and Best Food Holding as its investment and operational management platforms to tap opportunities in healthcare and other industries.

More information

About Hillhouse Capital Group

Hillhouse Capital Group is a leading investment management firm. Founded by Lei Zhang in 2005, Hillhouse invests with a long-term time horizon, and independent proprietary research is key to its investment process. The team focuses on the consumer, TMT, industrial and healthcare sectors and invests in companies across all equity stages. Hillhouse manages capital for institutional clients such as university endowments, foundations, sovereign wealth funds, pensions and independent family-run institutions.

More information

About Hopu Investment

Hopu is a leading private equity investment firm founded by Mr. Fang Fenglei in 2008. Hopu has more than US$12 billion under management to date.

More information

About CDH Investments

Established in 2002, CDH Investments is one of the leading alternative investment fund managers focused on China today with over US$17 billion of assets under management, as of December 31, 2017. CDH was founded by Wu Shangzhi, Jiao Shuge and four other investment professionals who worked together in the direct investment department of China International Capital Corporation.

More information

About Qianhai Fund of Funds LLP

The Qianhai Fund of Funds is a Limited Liability Partnership fund of funds set up in accordance with the Shenzhen Municipality’s plan to support the private investment ecosphere and favorable tax policies via the new Qianhai economic district. The central government of China State Council document, “Supporting Related Policies of Development and Opening in Shenzhen Qianhai, a Shenzhen and Hong Kong Modern Service Industry Cooperation District”, also supports a domestic fund of funds for venture capital and private equity. 
The Qianhai Fund of Funds LLP (Qianhai FoF) established December 2015 has initial assets under management (AUM) of RMB 28.5 billion. The successful founding of the Qianhai Fund of Funds LLP marks the completion of the fourth of eight items for financial innovation as laid out by the State Council. The Qianhai FoF is of epoch-making significance as it pushes forward China’s private equity investment industry by introducing an accredited investors model to the industry and transforming the local private investment industry with the emergence of professional limited partners. 

More information

About Rainbow Capital

Rainbow Capital is a Hong Kong based single family office of Mr. Jacky Xu, Founder and Chairman of Trendy International Group, a leading global conglomerate that delivers a range of fashion and lifestyle services. Mr. Xu is also an angel investor of VIPShop Holdings Limited and has served as a director of the company since 2011. Rainbow Capital manages the family's transgenerational long-term capital over US$ 1billion, focused on innovation-driven technology and healthcare sectors.

More information


US (Office)

Suite 500, 2275 Research Blvd, Rockville, Maryland, 20850, USA

Tel: +1 301-670-2800 ex 1990

Beijing (Office)

Rm 15A02,15A/F, Dacheng Plaza, 127 Xuanwumen West Street, Xicheng District, Beijing, China 100031

Tel: + 86-10-5617 7946

Shanghai (Headquarter)

Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District, Shanghai, China, 201210

Tel: +86-21-6057 8000

Copyright I-MAB Biopharma Co., Ltd. all rights reserved 2019 沪ICP备17007960号-1